Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

0.9300 -0.0100 (-1.06%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chemomab Therapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver... 
Via Benzinga
Chemomab Therapeutics Announces $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
Chemomab Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
From Chemomab Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
Chemomab Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024. 
Via Benzinga
Topics Intellectual Property
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic this morning as we check out all of the winners and losers worth keeping tabs on for Thursday! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! 
Via InvestorPlace
Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of The Children's Place, Inc. (NASDAQ: PLCE) moved lower during Thursday’s session following weak quarterly earnings. 
Via Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! 
Via InvestorPlace
Crude Oil Falls 2%; TJX Issues Weak Earnings Outlook
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 150 points on Wednesday. The Dow traded up 0.46% to 34,989.30 while the NASDAQ rose 0.16% to 14,116.28. The S&P... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS